In this scenario, different approaches have been investigated to re-activate radioiodine uptake in cancer cells by upregulating NIS expression and/or recovering its function in RAI-resistant tumors, including the use of protein kinase inhibitors as redifferentiation agents [10, 11]. The gene discussed is SLC5A5; the disease is cancer.